Targeting EGFR Alterations: Precision Approaches to Frontline Treatment of Late-Stage Non-Small Cell Lung Cancer (NSCLC)

To provide optimal patient care, community and VHA oncologists, nurses, pharmacists, other health care professionals who treat patients with lung cancer must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with late-stage NSCLC with EGFRm and the clinical utility of agents that could significantly impact patient outcomes. In the past, individuals with late-stage EGFRm NSCLC had a large and unmet need for safe and effective therapies. However, evolving precision medical approaches, which use genetic testing to detect specific EGFRm and to identify patients who are eligible for the corresponding targeted therapies, have significantly improved outcomes for these patients. Now that a variety of therapy choices are available, clinicians in the VA and community oncology settings must stay informed of new guidelines, understand the relevant trial data, and properly coordinate within MDC teams to identify and manage AEs and to allow for optimal patient experiences and outcomes.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Pricing

Free

Reported to ACCME by the provider

Conference / congress
Credit · Up to 1 credit
Commercial Support

Released

Feb 9, 2026
Last day to claim credit

Feb 10, 2027 4 months left

Student Flex	$18.75/mo
Professional Flex	$60/mo
Student 3-Year	$100
Student 2-Year	$112.50

Targeting EGFR Alterations: Precision Approaches to Frontline Treatment of Late-Stage Non-Small Cell Lung Cancer (NSCLC)

Related courses

More from Medical Education Resources